Key Highlights

  • Loss per share was USD 3.23 against an estimate of a USD 3.54 loss.
  • Net loss was USD 94.23 million, against USD 73.93 million a year earlier.
  • General and administrative expense was USD 42.71 million, against USD 12.56 million.
  • Cash and marketable securities were USD 1.3 billion at September 30.

Praxis Precision Medicines (NASDAQ:PRAX) reported a third quarter 2026 loss per share of USD 3.23, against an estimate of a USD 3.54 loss and a USD 3.36 loss in the third quarter of 2025. Net loss was USD 94.23 million, compared with USD 73.93 million in the prior-year quarter.

The loss from operations was USD 106.91 million, against USD 78.36 million a year earlier. The company reported the figures in its quarterly filing for the period ended September 30, 2026, and described a portfolio of four late-stage product candidates across movement disorders and epilepsy.

Operating Expenses

Total operating expenses were USD 106.91 million, compared with USD 78.36 million in the third quarter of 2025. Research and Development expense was USD 64.21 million, against USD 65.80 million, while general and administrative expense was USD 42.71 million, against USD 12.56 million.

For the nine months ended September 30, 2026, total operating expenses were USD 309.68 million, against USD 229.15 million. Research and development expense for the nine months was USD 211.61 million, compared with USD 189.61 million, and general and administrative expense was USD 98.07 million, against USD 39.55 million.

Net loss for the nine months was USD 270.52 million, compared with USD 214.36 million in the same period of 2025. The nine-month loss per share was USD 9.31, against USD 9.97.

The filing reports cash and cash equivalents of USD 361.85 million at September 30, 2026, compared with USD 357.33 million at the prior Balance Sheet date. Marketable securities were USD 383.47 million, compared with USD 242.00 million.

Pipeline and Regulatory Submissions

The filing states the company submitted a New Drug Application to the FDA for ulixacaltamide HCl for the treatment of essential tremor, based on positive results from two studies in its Phase 3 Essential3 program. It also submitted an NDA for relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, based on results from a registrational cohort.

For vormatrigine, the filing describes updates to study design that incorporate learnings from the POWER1 study and says the company is finalizing the design of POWER3, a clinical trial evaluating vormatrigine as a single-agent treatment for focal onset seizures, with initiation planned in 2027. For elsunersen, the company announced positive topline results in April 2026 from the EMBRAVE Part A study.

Liquidity

As of September 30, 2026, the company had cash, cash equivalents and marketable securities of USD 1.3 billion. The filing states the company believes this amount is sufficient to fund its operating and Capital Expenditure requirements to advance its research efforts and Clinical Trials for at least one year from the date the financial statements were issued.

Praxis Precision Medicines Q3 2026 Earnings: Key Takeaways

Praxis Precision Medicines reported a third quarter 2026 loss per share of USD 3.23 and a net loss of USD 94.23 million. Total operating expenses were USD 106.91 million, and cash, cash equivalents and marketable securities were USD 1.3 billion.